BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/31/2021 6:51:26 AM | Browse: 345 | Download: 612
 |
Received |
|
2021-02-02 05:04 |
|
Peer-Review Started |
|
2021-02-02 05:16 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-11 21:21 |
|
Revised |
|
2021-05-24 03:12 |
|
Second Decision |
|
2021-07-19 03:12 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-07-19 04:50 |
|
Articles in Press |
|
2021-07-19 04:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-07-29 11:21 |
|
Typeset the Manuscript |
|
2021-08-25 08:30 |
|
Publish the Manuscript Online |
|
2021-08-31 06:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li Zhang, Jing Wang, Ling-Zhi Cui, Kai Wang, Ming-Ming Yuan, Rong-Rong Chen and Li-Jiao Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Li-Jiao Zhang, MM, Chief Physician, Professor, Department of Cadre Health, Shanxi Provincial Cancer Hospital, Employee Xincun No. 3, Xinghualing District, Taiyuan 030013, Shanxi Province, China. zljsx66@126.com |
| Key Words |
Non-small cell lung cancer; Next-generation sequencing; BRCA2 gene; Poly (adenosine diphosphate-ribose) polymerase inhibitor; Case report |
| Core Tip |
The clinical evidence for successful off-label use of targeted drugs for lung adenocarcinoma patients following progression on multiple lines of treatment is still lacking now. Herein, we describe the identification of a germline BRCA2 mutation in a lung adenocarcinoma patient. The patient had multiple refractory brain metastases and received olaparib combined with gefitinib and recombinant human endostatin following progression on multiple lines of treatment, with a progression-free survival of 13.5 mo. This case provides unequivocal clinical evidence for the off-label use of olaparib in lung adenocarcinoma patients with a BRCA mutation after disease progression. |
| Publish Date |
2021-08-31 06:51 |
| Citation |
Zhang L, Wang J, Cui LZ, Wang K, Yuan MM, Chen RR, Zhang LJ. Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report. World J Clin Cases 2021; 9(25): 7498-7503 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i25/7498.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i25.7498 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
